These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373 [TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
7. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors. Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879 [TBL] [Abstract][Full Text] [Related]
8. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Saif MW Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. Janson ET J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863 [TBL] [Abstract][Full Text] [Related]
10. Pancreatic neuroendocrine tumors: a review. Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686 [TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329 [TBL] [Abstract][Full Text] [Related]
16. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A Tumori; 2011; 97(5):620-8. PubMed ID: 22158494 [TBL] [Abstract][Full Text] [Related]
17. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues. Khagi S; Saif MW JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324 [TBL] [Abstract][Full Text] [Related]